Cannabis Law Report

DECEMBER 23, 2021

DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. This report has been compiled to assist interested parties in understanding the market for the medical use of cannabinoids and where it may be heading. GW Pharmaceuticals.

Pharmaceutical 74

Pharmaceutical Clinical Trials Research and Development Cannabinoids 74

Cannabis Law Report

JULY 12, 2019

International Cannabinoid Cancer Research Institute (Draft 5). This paper seeks to answer why refined cannabinoids have more side effects than the natural cannabis product, as well as the possible etiology of said adverse reactions. Also discussed are other attempts at affecting the cannabinoid system from a singular standpoint.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? What do experts say? September 23, 2019.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. Cannabinoids Many of the components found in Cannabis plants are known as cannabinoids. Cannabinoids will interact with neurological receptors in the human body in the same way that naturally occurring chemicals would.

Epilepsy 100

Epilepsy Pharmaceutical Cannabinoids THC 100

Cannabis Law Report

JULY 26, 2021

SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. TEL AVIV, Israel , July 26, 2021 /PRNewswire/ — SciSparc Ltd.

Research and Development 105

Research and Development Supply Chain Pharmaceutical Treatment 105

Otherside Farms

JANUARY 24, 2019

Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. During the past couple of decades, investigators have discovered two different types of cannabinoid receptors in the brain, spinal cord, and peripheral tissues, including immune tissues.

Clinical Trials 45

Clinical Trials Epilepsy Marijuana Pharmaceutical 45

Canna Law Blog

MARCH 12, 2019

9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.

Epilepsy 87

Epilepsy Pharmaceutical Cannabinoids CBD 87

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Pharmaceutical 98

Pharmaceutical Research and Development Epilepsy Medicine 98

The Cannigma

JUNE 15, 2021

Cannabidiol (CBD) belongs to a class of molecules called cannabinoids , which are produced almost exclusively in cannabis — hence the name. The two cannabinoids can also cause very different effects in other ways. CBD is also often compared to CBG (cannabigerol) , another increasingly popular cannabinoid. CBD vs CBDA.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Veriheal

AUGUST 9, 2023

Recent research reaffirms earlier studies that claim that certain non-marijuana plants contain similar compounds found in cannabis, often called cannabinoids. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids. Some have even explored it for its aphrodisiac potential.

CBD 96

CBD Cannabinoids THC Extraction 96

The Cannigma

JUNE 1, 2021

Patients can take part if they have a medical condition which has not responded to pharmaceutical drugs. Some of the qualifying health conditions include epilepsy, neuropathic pain, chemotherapy side effects, a need for palliative care, and pain linked to multiple sclerosis, according to France24.

Law 112

Law Epilepsy Programs Patients 112

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [press release]. Epilepsy Behav. phosphorus, potassium, and calcium).

CBD 144

CBD Seed-To-Sale Food Access 144

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

The two active cannabinoids in marijuana are cannabidiol (CBD) and tetrahydrocannabinol (THC), the latter of which causes psychoactive effects while the former does not. This system naturally produces cannabinoids in the bloodstream, but chronic stress, anxiety, and other stimuli can stifle the production of natural endocannabinoids.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

MedicalJane

OCTOBER 3, 2019

The United States Department of Defense and GW Pharmaceuticals are collaborating on a new clinical trial at the Montefiore Medical Center in New York. The study examines the effect of the cannabinoid Cannabidivarin, more commonly referred to as CBDV , on irritability and repetitive behaviors in children with autism spectrum disorder.

Clinical Trials 74

Clinical Trials Epilepsy Pharmaceutical Treatment 74

Puff Puff Post

OCTOBER 3, 2019

Previous success from treating epilepsy with Cannabinoids now motivates doctors to investigate the plant’s effectiveness in treating symptoms of autism. Montefiore Medical Center in New York and GW Pharmaceuticals are examining the effects of a cannabis compound when administered to children on the autism spectrum.

Research and Development 94

Research and Development Epilepsy Clinical Trials Treatment 94

The Cannigma

MARCH 7, 2022

So much attention is placed upon THC and CBD that sometimes the less abundant cannabinoids are forgotten about or not appreciated fully. Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Common cannabinoids in cannabis. How can you take CBN?

THC 139

THC Sleep Clinical Trials Cannabinoids 139

Canna Law Blog

OCTOBER 31, 2019

Epidiolex is a drug that was created by Cambridge, UK-based GW Pharmaceuticals and was approved by the FDA as a drug in 2018 to help relieve epilepsy-induced seizures. GW Pharmaceuticals has now done two decades’ worth of research on CBD and other cannabinoids and is responsible for putting CBD on the FDA’s radar many years ago.

Pharmaceutical 71

Pharmaceutical Research and Development Cannabinoids Food 71

Peninsula Alternative Health

MAY 15, 2019

Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states. Because nearly one-third of patients with epilepsy are not getting the results they want from conventional treatments, they are eager to experiment with natural cannabinoid therapy. References Staff, T.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

The Cannigma

FEBRUARY 4, 2021

Dronabinol, the pharmaceutical name for ?9-tetrahydrocannabinol While the approval covered a synthetic version of the most famous cannabinoid, it is chemically indistinguishable from the version naturally produced by the cannabis plant. The FDA has approved (separate) drugs with the active ingredients THC and CBD. . Shutterstock).

Cannabinoids 145

Cannabinoids THC Blood Pressure Conditions 145

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Healthcare Communications.

Pharmaceutical 51

Pharmaceutical Clinical Trials Research and Development Programs 51

SpeedWeed

JULY 29, 2021

In addition to THC and CBD, hemp and cannabis contain dozens of other cannabinoids that can aid everything from appetite suppression and weight loss to fighting insomnia or inflammation. This amazing cannabinoid is THCV (tetrahydrocannabivarin). . This rare cannabinoid is formed when THC degrades due to age or heat.

Sleep 52

Sleep Cannabinoids Oil THC 52

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

CannaMD

JULY 14, 2020

Due to many common pharmaceuticals being tested mainly on younger patients who aren’t dealing with multiple conditions, unforeseen problems often occur when older patients end up being prescribed multiple medications at a time. However, it’s not just older patients who encounter problems with polypharmacy. Anti-inflammatory. Antiemetic.

Marijuana 105

Marijuana Conditions Patients Epilepsy 105

Veriheal

MAY 17, 2021

Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” That is perhaps the biggest lie that is being perpetuated on the Alabama public today. ” State Doctors Oppose Legalization in Alabama.

Legalization 93

Legalization Pharmaceutical Therapy Chronic Pain 93

Veriheal

SEPTEMBER 27, 2021

Individuals with this condition have to find ways to deal with the fact that their immune system is attacking the protective sheath of nerve fiber surrounding the nerve cells, putting the body in a state of imbalance that results in muscle spasms, paralysis, disrupted bladder function, mental changes, depression, and even epilepsy.

Treatment 98

Treatment Patients Access Research and Development 98

CannaTech

AUGUST 9, 2018

We are delighted to introduce you to some new friends set to make a big impact on the medical cannabis advocacy scene… the creators of a new documentary called Separating the Strains ; a deeply personal narrative that charts the reality of living with epilepsy, with and without cannabis medication as a treatment option.

Strains 69

Strains Epilepsy Advocacy Medicine 69

Alchimia

JUNE 20, 2016

CBD is a cannabinoid present in cannabis plants with a very similar molecular structure to THC but without any kind of psychoactive effect. It has been demonstrated that CBD has low affinity with the CB1 and CB2 cannabinoid receptors , but it does act on other receptors of the human body like GPR55 or 5-HT1A. What is CBD?

Medicine 76

Medicine CBD Research and Development Epilepsy 76

Marijuanally

AUGUST 30, 2018

With the medical world embracing this cannabinoid medicinal properties, consumers are left with a plethora of questions. CBD or Cannabidiol is a cannabinoid that can be found within the cannabis plant. CBD, unlike THC [the psychoactive cannabinoid], won’t get you high. CBD is a hot topic these days. Which one is better?

Topical 73

Topical CBD Hemp Cannabinoids 73

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. Chris Chapman, M.D.,

Pharmaceutical 40

Pharmaceutical Data CBD Clinical Trials 40

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 40

Pharmaceutical Clinical Trials Chronic Pain Therapy 40

CannaMD

AUGUST 8, 2020

In honor of National CBD Day, CannaMD wants to clear up some cannabinoid confusion once and for all. However, many of these products contain a number of other cannabinoids as well. To understand cannabinoids, we need to take a closer look at the endocannabinoid system. CBD Scheduling Rule Change.

CBD 105

CBD DEA Research and Development Hemp 105

Cannabis Law Report

NOVEMBER 29, 2019

For instance, THC has shown the potential to help in the treatment of conditions like PTSD, depression, eating disorders, and epilepsy. When a person uses a THC oil pen ( vapingdaily gives more details) to ingest this cannabinoid, it can benefit them in different ways. However, cannabinoids use modulation. THC Oil Benefits.

Oil 80

Oil THC Cannabinoids Research and Development 80

Canna Care Docs

SEPTEMBER 18, 2020

A medical provider may recommend medical cannabis to treat any condition that they feel may benefit from medical cannabis and cannabinoid-based therapies. These bills created the affirmative defense for possession of THC-A oil for the treatment of epilepsy. What Conditions Qualify for Medical Marijuana Cards in Virginia?

Pharmaceutical 98

Pharmaceutical Conditions Patients Oil 98

Leaf Science

JULY 23, 2019

In spite of this, research has shown that THC as much as the other cannabinoids present in cannabis has medicinal value to humans. In the UK, cannabis was legalized for medicinal purposes in 2018 which saw patients of epilepsy and multiple sclerosis able to access pharmaceutical cannabis derivatives such as Sativex and Epidiolex.

Strains 74

Strains Epilepsy Cannabinoids THC 74

United Patients Group

FEBRUARY 2, 2023

It’s made up of endocannabinoids and cannabinoid receptors, which work together to maintain homeostasis in the body by regulating things like mood, energy, appetite and sleep cycles. The ECS has been studied for its role in many diseases including cancer , epilepsy, chronic pain and multiple sclerosis (MS). antibiotics).

Blood Pressure 105

Blood Pressure Sleep Chronic Pain Digestion 105

United Patients Group

APRIL 18, 2023

Because they often combine it with other drugs like cocaine or heroin or even legal ‘prescribed’ pharmaceuticals–and those are far more dangerous than cannabis itself! The US federal government even owns a patent on cannabinoids for use as a neuroprotectant! So why do you hear about people dying from smoking weed?

Research and Development 116

Research and Development Indica Treatment Conditions 116

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98